Since the passage of the Orphan Drug Act in 1983, the rare disease patient community has been an active force in the advancement of research and innovation in clinical trials. This session explores the history of clinical research targeting rare diseases, the role rare disease patient advocates have played in advancing innovative clinical research methodologies (including decentralized clinical trials), and what the broader clinical research community can learn from the rare disease community about recruitment and diversity in clinical trials.

CEU: 1.00 ACRP

Speaker:

Stephanie Christopher, MA, CCRC, FACRP, Director, Patient Advocacy, Pfizer

Watch a Sneak Peek into the Session Content: